Last edition
News about "Mitsubishi Tanabe Pharma "
GV20 Therapeutics Hits Milestone in ADC Collaboration with Mitsubishi Tanabe Pharma
GV20 Therapeutics has secured a milestone payment from Mitsubishi Tanabe Pharma under their 2025 collaboration to develop the first-in-class Antibody Drug Conjugates (ADCs) using GV20’s STEAD AI–discovered tumour-targeting antibodies.
Mitsubishi Tanabe Pharma | 28/11/2025 | By Dineshwori
Synaffix Signs License Deal with Mitsubishi Tanabe Pharma for ADC Technology
Synaffix is responsible for the manufacturing of the components that are related to its proprietary technologies, and MTPC is responsible for the research, development, manufacturing and commercialization of the ADC.
Mitsubishi Tanabe Pharma | 13/01/2025 | By Aishwarya | 217
Martin Pharmaceuticals Gets Exclusive Rights from MTPC for Docarpamine
The Phase 2a open-label trial enrolled 16 patients with refractory ascites requiring regular large-volume paracentesis (LVP).
Mitsubishi Tanabe Pharma | 04/12/2024 | By Aishwarya | 360
Moderna and Mitsubishi Tanabe Pharma to Promote mRNA Respiratory Vaccine in Japan
Moderna, Inc. has signed a joint agreement with Mitsubishi Tanabe Pharma regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including Moderna's COVID-19 vaccine, Spikevax.
Mitsubishi Tanabe Pharma | 15/07/2024 | By Aishwarya | 483
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy